Randomized placebo-controlled EPPIC trials of AST-120 in CKD
G Schulman, T Berl, GJ Beck, G Remuzzi… - Journal of the …, 2015 - journals.lww.com
Reduced GFR in patients with CKD causes systemic accumulation of uremic toxins, which
has been correlated with disease progression and increased morbidity. The orally
administered spherical carbon adsorbent AST-120 reduces systemic toxin absorption
through gastrointestinal sequestration, which may slow disease progression in these
patients. The multinational, randomized, double-blind, placebo-controlled Evaluating
Prevention of Progression in CKD (EPPIC)-1 and EPPIC-2 trials evaluated the effects of AST …
has been correlated with disease progression and increased morbidity. The orally
administered spherical carbon adsorbent AST-120 reduces systemic toxin absorption
through gastrointestinal sequestration, which may slow disease progression in these
patients. The multinational, randomized, double-blind, placebo-controlled Evaluating
Prevention of Progression in CKD (EPPIC)-1 and EPPIC-2 trials evaluated the effects of AST …